Contract Development Services

Hovione plans to continue to expand its sites in Portugal and Ireland for chemical synthesis, spray drying, and laboratory analysis.

A $800-million acquisition of MPI Research expands Charles River's offerings for early-stage contract research.

The companies will partner to further immuno-oncology research using humanized mice.

Mark Egerton, PhD, chief executive officer of Quotient Sciences, shares insights on a new approach to accelerate drug development, which integrates formulation development, real-time adaptive GMP manufacturing, and clinical research within a single platform.

Avista Pharma's strengthens early phase drug development offerings with acquisition of Solid Form Solutions.

Successful outsourcing relationships in early phase drug-development analytics are driven by partnership.

CRLs put the brakes on drug development and damage corporate reputation and stock prices. Upfront investment and better sponsor oversight are ways to prevent them.

Research suggests that working with a single contract partner can reduce development time and improve economics.

Joe DiMasi, director of economic analysis and research associate professor, Tufts Center for the Study of Drug Development (CSDD), discussed research into the impacts of working with single source contractors with Pharmaceutical Technology.

The companies will be integrated to form the newly-branded AGC Biologics, which will specialize in customized contract development and manufacturing organization services for the scale-up and cGMP manufacture of protein-based therapeutics.

Flexibility, innovation, and creativity are critical for success in navigating the challenges facing the bio/pharmaceutical industry.

KBI Biopharma's acquisition of Elion Labs expands KBI's biophysical and analytical characterization capabilities.

The acquisition strengthens Charles River Laboratories’ capabilities in the oncology and immunology therapeutic areas.

Pharma trends translate into increased need for not only external partners, but those will capabilities that can help advance today’s drug development and manufacturing challenges.

The companies will collaborate to produce and improve the recombinant properties of Aethlon’s Hemopurifier blood purification device.

The acquisition broadens the CDMO’s preclinical and clinical offering to include bioanalytical and drug discovery services.

Catalent Applied Drug Delivery Institute announced a partnership with Rutgers University to examine the challenges of pediatric drug formulation and delivery.

The new center will help biopharmaceutical and pharmaceutical manufacturers with product development.

Catalent expands the scope of the OptiForm Solution Suite to bridge gap from late-stage discovery to Phase I trials.

GE Healthcare’s Dharmacon business and CordenPharma contract manufacturing enter a strategic collaboration to accelerate the oligonucleotide development process.

How has the bio/pharmaceutical contract manufacturing industry evolved over the years and what does the future hold?

Advances in process analytical technology have been achieved, but significant challenges remain.

A case study reviews the reformulation and scale up of high drug load prototype using wet granulation process for a model formulation.

Catalent announces a development agreement with JOT to evaluate softgel options for a resveratrol drug candidate.

The new facility will focus on formulation development, drug product analytical development, and quality control.